drugset / Trial / NCT04781959

A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy

NCT04781959

Phase 4 Completed 233 enrolled Ottawa Hospital Research Institute
RandomizedParallel-groupOpen-labelTreatment

Summary

REaCT-5G will compare bone pain from a single dose of Pegfilgrastim to 5 doses of daily filgrastim in breast cancer patients receiving neoadjuvant/adjuvant chemotherapy.

Timeline

Start
2021-06-09
Primary completion
2023-02-23
Completion
2023-09-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pegfilgrastim Protein / enzyme biologic Subcutaneous
Comparator filgrastim Protein / enzyme biologic Subcutaneous

Indications